3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
HIV Infections
2
Sarcoma, Kaposi
1
Lymphoma, AIDS-Related
1
Dendritic Cell Sarcoma, Interdigitating
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cyclophosphamide
64
fludarabine phosphate
37
Peripheral Blood Stem Cell Transplantation
30
Cyclosporine
30
Radiotherapy
28
Mycophenolic Acid
28
Filgrastim
28
Busulfan
28
Whole-Body Irradiation
26
Antilymphocyte Serum
24
Melphalan
19
Etoposide
19
Tacrolimus
16
Methotrexate
16
Cord Blood Stem Cell Transplantation
16
Methylprednisolone
15
Rituximab
14
Thiotepa
10
Cytarabine
10
Vincristine
8
Prednisone
8
Doxorubicin
8
Carboplatin
7
fludarabine
5
Sirolimus
5
sargramostim
4
glofitamab
4
aldesleukin
4
Therapeutics
4
Leucovorin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Dendritic Cell Sarcoma, Interdigitating
×
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
×
Clear all
NCT00799136
2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2
Completed
6 enrolled